{"id":1910,"date":"2021-12-02T11:15:55","date_gmt":"2021-12-02T10:15:55","guid":{"rendered":"http:\/\/invivo.partners\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/"},"modified":"2021-12-02T11:42:41","modified_gmt":"2021-12-02T10:42:41","slug":"integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures","status":"publish","type":"post","link":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/","title":{"rendered":"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[501],"tags":[564,530,544],"class_list":["post-1910","post","type-post","status-publish","format-standard","hentry","category-noticias","tag-integratx-es","tag-invivo-capital-es","tag-invivo-ventures-es"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures - Invivo Partners<\/title>\n<meta name=\"description\" content=\"The biotechnology company, which specialises in gene editing and was founded by researchers Marc G\u00fcell and Avencia S\u00e1nchez-Mej\u00edas of Pompeu Fabra University, got its start in Barcelona. The investment will be used to develop an innovative gene editing platform with the potential to make advanced therapies safer and more effective.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"The biotechnology company, which specialises in gene editing and was founded by researchers Marc G\u00fcell and Avencia S\u00e1nchez-Mej\u00edas of Pompeu Fabra University, got its start in Barcelona. The investment will be used to develop an innovative gene editing platform with the potential to make advanced therapies safer and more effective.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-02T10:15:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-02T10:42:41+00:00\" \/>\n<meta name=\"author\" content=\"invivo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"invivo\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/\"},\"author\":{\"name\":\"invivo\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\"},\"headline\":\"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures\",\"datePublished\":\"2021-12-02T10:15:55+00:00\",\"dateModified\":\"2021-12-02T10:42:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/\"},\"wordCount\":16,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"keywords\":[\"integratx\",\"Invivo capital\",\"Invivo Ventures\"],\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/\",\"url\":\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/\",\"name\":\"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2021-12-02T10:15:55+00:00\",\"dateModified\":\"2021-12-02T10:42:41+00:00\",\"description\":\"The biotechnology company, which specialises in gene editing and was founded by researchers Marc G\u00fcell and Avencia S\u00e1nchez-Mej\u00edas of Pompeu Fabra University, got its start in Barcelona. The investment will be used to develop an innovative gene editing platform with the potential to make advanced therapies safer and more effective.\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789\",\"name\":\"invivo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g\",\"caption\":\"invivo\"},\"url\":\"https:\/\/invivo.partners\/es\/author\/invivocapital\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures - Invivo Partners","description":"The biotechnology company, which specialises in gene editing and was founded by researchers Marc G\u00fcell and Avencia S\u00e1nchez-Mej\u00edas of Pompeu Fabra University, got its start in Barcelona. The investment will be used to develop an innovative gene editing platform with the potential to make advanced therapies safer and more effective.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/","og_locale":"es_ES","og_type":"article","og_title":"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures - Invivo Partners","og_description":"The biotechnology company, which specialises in gene editing and was founded by researchers Marc G\u00fcell and Avencia S\u00e1nchez-Mej\u00edas of Pompeu Fabra University, got its start in Barcelona. The investment will be used to develop an innovative gene editing platform with the potential to make advanced therapies safer and more effective.","og_url":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/","og_site_name":"Invivo Partners","article_published_time":"2021-12-02T10:15:55+00:00","article_modified_time":"2021-12-02T10:42:41+00:00","author":"invivo","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"invivo"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/"},"author":{"name":"invivo","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789"},"headline":"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures","datePublished":"2021-12-02T10:15:55+00:00","dateModified":"2021-12-02T10:42:41+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/"},"wordCount":16,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"keywords":["integratx","Invivo capital","Invivo Ventures"],"articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/","url":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/","name":"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2021-12-02T10:15:55+00:00","dateModified":"2021-12-02T10:42:41+00:00","description":"The biotechnology company, which specialises in gene editing and was founded by researchers Marc G\u00fcell and Avencia S\u00e1nchez-Mej\u00edas of Pompeu Fabra University, got its start in Barcelona. The investment will be used to develop an innovative gene editing platform with the potential to make advanced therapies safer and more effective.","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/2021\/12\/02\/integra-tx-secures-e4-5-million-in-funding-from-invivo-capital-advent-france-biotechnology-and-takeda-ventures\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"Integra Tx cierra una ronda de 4,5 M\u20ac con Invivo Capital, Advent France Biotechnology y Takeda Ventures"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/f382d91fa1fbbe4bb94f3093438e5789","name":"invivo","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3c1e935daee28cd9cccdda9f9bb7f784c23881fa1325206e7c53c9119500139c?s=96&d=mm&r=g","caption":"invivo"},"url":"https:\/\/invivo.partners\/es\/author\/invivocapital\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts\/1910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/comments?post=1910"}],"version-history":[{"count":3,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts\/1910\/revisions"}],"predecessor-version":[{"id":1916,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/posts\/1910\/revisions\/1916"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=1910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/categories?post=1910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tags?post=1910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}